Drug intelligence / Profile preview

ganitumab + folinic acid + fluorouracil + irinotecan

Development stage: Unknown
Lead developer: Amgen
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

**AMG 479 + FOLFIRI** refers to the combination of ganitumab (AMG 479), a fully human monoclonal antibody targeting the insulin-like growth factor 1 receptor (IGF1R), with the FOLFIRI chemotherapy regimen, which consists of folinic acid (leucovorin), fluorouracil (5-FU), and irinotecan. Ganitumab blocks IGF1R, thereby inhibiting tumor cell proliferation and survival. FOLFIRI acts by disrupting DNA synthesis and mitosis in rapidly dividing cancer cells, primarily used in gastrointestinal cancers. This combination is under clinical investigation for use in advanced solid tumors, particularly metastatic colorectal cancer[1][3][2][4].

Other names: ganitumab + FOLFIRI

Targets

IGF-1R (Insulin-like growth factor 1 receptor)TS (Thymidylate synthase)TOP1 (DNA Topoisomerase I)

Beyond the preview

Go deeper on ganitumab + folinic acid + fluorouracil + irinotecan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ganitumab + folinic acid + fluorouracil + irinotecan.

Explore the full profile